This story was originally published May 10.

Sequenom's 35,000 MaterniT21 Plus tests that it accessioned in the first quarter of 2013 helped drive its 158 percent spike in revenues to $38.5 million from $14.9 million in the first quarter of 2012, the company said last week during a conference call discussing its financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.